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Objectives of the present study were to evaluate neonatal Holstein heifer
performance while supplemented with coccidiostat (CX), yeast (YST), β-glucan or some
combination of these products in non-medicated milk replacer. Efficacy of these products
on E. coli and coccidia shedding was also observed. No differences (P > 0.05) were
observed among treatment groups with respect to performance data collected which
included growth, feed intake and efficiency, fecal and respiratory and blood parameters.
Heifers fed YST or YST + β-glucan had higher (P = 0.02 and P < 0.01, respectively)
fecal E. coli concentrations compared to heifers fed CX, CX + YST, or β-glucan. No
heifers showed clinical signs of coccidiosis and appeared to be healthy. These results
suggest neonatal heifers may be supplemented with yeast derivatives without negative
effects on growth or health performance.
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CHAPTER I
INTRODUCTION
Finding alternatives for sub-clinical antibiotic use in production animals is being
encouraged not only by those in the medical community, but also by consumers. From
the medical standpoint, it is believed that human pathogens are becoming resistant to
certain antibiotics due to the sub-clinical use of antibiotics in animals that are reared for
consumption and the potential for translation of these antibiotics into the food product.
The administration of an antimicrobial, usually as a feed additive, over a period of time,
to growing animals that results in improved physiological performance, is the definition
of growth promotion given by, Phillips et al. (2004). In the 1940’s, chickens were fed byproducts of tetracycline (an antibiotic) and were found to grow faster than those not fed
the by-products. This is when growth promoting effects of antibiotics were first
discovered (Stokestad et al., 1949). Since this discovery, poultry, swine and cattle
producers have utilized some antibiotics or derivatives, as growth promoters and gut
health enhancers. Phillips et al. (2004) states that antimicrobials are an integral part of
efficient and humane livestock production, as growing the best animal in the shortest
length of time with the least amount of disease interference is a main objective in
livestock production. Swine producers use therapeutic antibiotics at weaning to treat
gastrointestinal disorders and then later in life to treat pneumonia, whereas cattle
producers use antibiotics mostly to treat respiratory infections in calves and mastitis in
cows. It is believed that the problem with human resistance to certain antibiotics may also
1

be caused by the over-use of antibiotics by humans and not just from the use in animals
(Phillips et al., 2004). Consumers today are more health conscious than in years past and
for this reason, producers aim to raise production animals to the standard in which the
consumers feel comfortable buying and consuming their products. In March of 2009,
Representative Louise Slaughter proposed to amend the Federal Food, Drug, and
Cosmetic Act. The proposed bill, Preservation of Antibiotics for Medical Treatment Act
of 2009, would eliminate the use of Critical Antimicrobial Animal Drugs, which are
defined as drugs used for treatement in both humans and animals: Penicillin, tetracycline,
macrolide, lincosamide, steptogramin, aminoglycoside and sulfonamide. Upon approval
of this bill, these drugs will not be usable as a non-therapeutic drug (Library of Congress,
2009). In 2002, the National Animal Montoring System (NAHMS) conducted a study
that represented 83% of the U.S. dairies and 85.7% of the total dairy cow population in
the United States. Data for the study was collected from February 2002 to January 2003.
The purpose of the study was to provide information about on farm antibiotic use to
participants and industry. Data was collected on cows, unweaned heifers, weaned heifers
and medicated milk replacer. The most common problem that required antibiotic
treatment for cows was mastitis (16.3%) and of those infected, 91.9% were treated with
an antimicrobial. Of the participants in the present only 14.7% used antimicrobials in
weaned heifer rations compared to 82.6% who did not. The majority of antimicrobial use
in unweaned heifers is due to diarrhea and/or digestive problems (15.3%) rather than
respiratory disease (9.0%), while respiratory diseases are treated more often (95.6%) with
antimicrobials compared to diarrhea/digestive problems (85.7%). Medicated milk
replacers were utilized by 50.8% of the participants in this study, while the greatest
percentage of those were operations with 100 to 499 cows. The most commonly used
2

drug in medicated milk replacers was oxytetracycline (23.5%). With the potential
restriction of certain antibiotics, researchers are motivated to investigate the possibility of
using live yeast cultures, yeast cell wall products, and β-glucans to promote gut health
and reduce use of antibiotics in feed.
Advancements in biotechnology in recent years have allowed the use of microbial
cultures as feed additives (Görgülü et al., 2003). Among these additives, probiotics,
which has been defined as “a live microbial feed supplement which beneficially affects
the host animal by improving its intestinal balance”, are included (Fuller, 1989). In the
late 1800s and into the early 1900s, the dietary use of probiotics and prebiotics bloomed
as people became more interested in intestinal microbiology (Patterson and Burkholder,
2003). Along with probiotics, the use of prebiotics are also being evaluated as a
supplement for both humans and animals. The basic definition of a prebiotic is, “a
nondigestible food ingredient that beneficially affects the host by selectively stimulating
the growth and/or activity of one or a limited number of bacteria in the colon” (Gibson
and Roberfroid, 1995). Fructooligosaccharide products are the most commonly used
prebiotics at this time, however, there are many other oligosaccharides being investigated
(Patterson and Burkholder, 2003). Among these oligosaccharides used for both human
and animals, mannanoilgosaccharides are used as a prebiotic, but they do not selectively
enrich beneficial bacterial populations. Instead, they are thought to bind and remove
pathogens from the intestinal tract, which results in immune system stimulation (Spring
et al., 2000). Immune stimulation is enhanced due to the reduction of pathogen
colonization in the intestinal tissue that helps fight infection (Patterson and Burkholder,
2003). Three of the possible alternatives being studied currently with and for dairy calves
are live yeast culture (Saccharomyces cerevisae), yeast cell wall products
3

(oligosaccharides), and β-Glucans (derivative of yeast). To date, the research conducted
thus far involving these three yeast derivatives has been very positive. Görgülü et al.
(2003) conducted a study using 24 male Holstein calves assigned to either the control or
the probiotic treatment group in two week intervals (used to eliminate time and age
effect) until there were 12 calves per treatment group. The probiotic treatment which
consisted of: Lactobacillus plantarum, L. bulgaricus, L. acidphilus, L. rhamnosus,
Bifidobacterium bifidum, Aspergillus orysa and Candida pintolopesii, was added to milk
during the morning feeding throughout the experimental period at a rate of 2 g per head
per day. Calves were fed whole milk, twice daily until weaned at 60 days of age. Growth
and health measures were recorded throughout the trial and calculated for 0-30, 30-60
and 0-60 d. Results from this study are based on 10 control calves and 12 probiotic fed
calves, due to death of calves from scours and/or bloat. The present study concluded that
calves supplemented with probiotics were superior in overall health compared to control,
however, there were no differences in growth performance. Average daily gain and feed
to gain ratio for the total experimental period for control and probiotic treatments were,
349.29 ± 53.36 g/d and 366.26 ± 29.68 g/d and 1.25 ± 0.24 and 1.44 ± 0.14, respectfully.
The total number of diarrhea and/or bloat cases were lower (3 cases) for the probiotic
treatment group compared to control (8 cases) group. Based on this information, Görgülü
et al. (2003) saw reduced treatment and medication cost for calves fed probiotics.

4

CHAPTER II
REVIEW OF LITERATURE
Coccidiostat Supplementation
In the United States, there are currently at least 13 different coccidial species
known with the ability to infect cattle, however, not all of them are pathogenic. The two
species that pose the greatest concern are: Eimeria bovis and Eimeria zuernii. Coccidia
typically infect the epithelial cells of the gut mucosa, but there are exceptions , Exception
number one is: the first generation schizonts (sporozoites that have undergone nuclear
division, of E. bovis are located in the endothelial cell of the small intestine, while the
second exception is the first generation schizonts of E. zuernii are located in the
connective tissue cells of the lamina propria (a loose layer of connective tissue located
just below the epithelium). If not treated properly, calves with coccidiosis normally die
from diarrhea or dehydration (Ernst and Benz, 1986). The lifecycle of coccidia take
approximately 21 d to complete. From d 1 to 15, the coccidia mature within the small
intestine, around d 16, the coccidia enter the large intestine and then is excreted between
days 17 and 21. The coccidia may stay in the environment until the oocyst are ingested at
which the lifecycle starts over (Quigley, 2001). Due to the persistence of coccidia in the
environment, the most effective treatment for coccidiosis is prevention. New
calvesshould be housed in a clean environment where feeding and water buckets should
be placed so there is limited fecal contamination. If contamination occurs, the chances of
calves ingesting coccidia oocyts increases, which may ultimately lead to infection
5

(coccidiosis). The prevalence of coccidiosis may be controlled or reduced by the use of
preventative drugs such as ionophores (lasalocid or monensin) and quinolones
(decoquinate), as used by in studies by Waggoner et al. (1994) and Heinrichs et al.
(1991). According to Ernst and Gerald (1986), coccidosis was first effectively treated in
chickens by flowers of sulfur in 1936. While this pioneer drug was too toxic to be used
for general purposes, it did encourage the discovery of a variety of sulfonamides which
were able to be used in chickens and other animals. Sulfonamides are still effective drugs
for treating coccidiosis, they are also used in human medicine, therefore, if the proposed
bill “Preservation of Antibiotics for Medical Treatment Act of 2009” gets passed, this
would result in the elimination of this particular class of drug. Another drug currently
being used to treat coccidiosis is Amprolium (Corid), according to Ernst and Gerald
(1986).
Research in Cattle
In 1990, Heinrichs et al. conducted a study to evaluate the effectiveness of
coccidiostat (decoquinate) on growth and health parameters in calves weaned early (4
wk) or conventionally (7wk). Forty-four Holstein calves were assigned to one of four
treatment groups; Early weaning/control grain, early weaning/ decoquinate grain,
conventional weaning/control grain, or conventional weaning/decoquinate grain. The
experimental design for the present study was a 2 x 2 factorial. Calves were initially
assigned to a respected weaning method and then to either control calf starter or starter
containing decoquinate. Calves fed grain with decoquinate were later fed control starter
after consuming their initial treated grain. This was to ensure total consumption of
decoquinate before being offered more grain with no additive. Decoquinate (Deccox,
6

Rhone-Poulenc, Atlanta, GA) was fed at a rate of 100mg/kg grain until weaning. Once
calves were weaned, those supplemented with decoquinate continued to be fed at a rate of
0.5mg/kg BW/d. All calves were fed whole milk at 10% of initial body weight twice
daily until 1 wk before weaning, at which 5% of initial body weight of milk was fed one
time daily. Grain was offered daily, while refusals were collected and weighed weekly.
Samples were collected weekly for feed analysis. After weaning, calves were moved
outdoors and placed in groups of 6 to 8 (by treatment) and remained on trial until 24 wk
of age. During this period, grain was fed at a rate of 3 kg/d along with free choice alfalfa
hay. Calves were weighed weekly until 8 wk of age and then biweekly through the
duration of the trial, while wither height, body length and heart girth were recorded
biweekly until 8 wk of age. Fecal scores were recorded and fecal samples were collected
from each calf one time per week until calves were 7 wk of age. Group-housed animals
had fecal samples collected weekly through the duration of the trial. Early weaned calves
had greater (P < 0.01) intakes of grain between weeks 5 and 7. There were no apparent
differences observed between weeks 8 and 24, meaning there were no long-term effects
to early weaning. Feed intake was not different, overall, for treated calves. Coccidia
counts were significantly lower in calves treated with decoquinate (P < 0.01), however,
the age of weaning had no effect. Actual coccidian counts for weaning treatment and
decoquinate treatment were: Early weaning (377.9), conventional weaning (196.1), no
decoquinate (535.4) and decoquinate (38.7). Conclusions from this study suggest treating
neonatal calves with decoquinate may reduce the number of coccidia oocysts shed in
feces. Also, early weaning had no negative long-term effects when compared to
conventional weaning. Waggoner et al. (1994) conducted a 56 d study to evaluate the
growth differences of calves fed lasalocid and decoquinate or a combination of the two
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additives. Lasalocid is the drug name for an antibacterial and coccidiostat, which is also
the active drug in the commonly used feed additive, Bovatec®. Sixty-four Holstein
calves between 15 and 17 wk of age with a mean BW of 185 ± 3 kg, were used in this
study; they were randomly assigned to one of four treatments. Treatments were: control
(unmedicated), lasalocid (Bovatec®,1.0 mg/kg of BW), decoquinate (Deccox®, 0.5
mg/kg of BW) or combination of lasalocid and decoquinate (1.0 mg/kg + 0.5 mg/kg of
BW, Bovatec® and Deccox®, respectfully). The combination group was fed the
additives at the same feeding rate, however, calves were fed the same recommended
feeding rate of decoquinate for the first 28 d on trial and then fed the recommended
feeding rate of lasalocid for the last 28 d on trail. Deccox® was fed to calves during the
first 28 d of trial because it is an anticoccidial treatment used to prevent calves from
being infected with coccidia before weaning, while Bovatec® was fed once calves were
weaned and placed into a group environment, the time at which coccidia oocyts are shed
in feces. Bovatec®, an ionophore, is a growth promoter, which helps calves during
stressful situations, such as weaning. Calves were housed in a single barn with four
calves per pen. One week before the study, qualitative fecal exams were conducted to
determine the presence of coccidial oosyts: E. zuernii and E. bovis. Oocyst numbers were
graded subjectively (rare, few, moderate, or many). Upon arrival at the Purdue University
Animal Science Research Farms, calves were weighed for 2 consecutive days and then
weekly for 56 d. Calves were also weighed consecutively on the final 2 d of the study.
Fecal samples were collected from each calf at the beginning of the trial and then weekly
for 8 wk. Daily body weight, DMI, and feed efficiency were calculated per pen. Results
for overall feed intake showed calves fed decoquinate had lower (6.76 kg/d, P < 0.05)
intakes when compared to calves fed lasalocid (7.00 kg/d, P < 0.05) or lasalocid plus
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decoquinate (7.07 kg/d, P < 0.05). Body weight gain for all calves was similar (P = 0.75)
with an average of 1.29 ± 0.03 kg/d over the duration of the 56 d trial. Waggoner et al.
(1994) noted, but did not show results for: lower oocyst shedding rates at wk 2 for all
treatment groups which caused a slight increase in body weight gain. There was an
increase shedding of oocyst at wk 6 among all treatment groups. During this time, all
calves exhibited a decreased body weight gain. Calves did not show signs of coccidial
infection, suggesting that coccidial infection may not be a major factor in rate of gain.
Feed efficiency was similar (P = 0.79) and averaged 0.189 ± 0.004 kg of gain/kg of DMI
for all treatment groups. Conclusions for this study suggest that under natural exposure to
coccidiosis, there was little advantage for medicating calves with lasalocid or decoquinate
at recommended dosages when compared to nonmedicated calves with respect to
increased gain and calf performance.
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Control

Treatment
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> 0.05
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0.79
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0.94

0.94

< 0.05

< 0.05

< 0.05

> 0.05

> 0.05
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P-value

Growth and intake performance of calves fed coccidostats, probiotics, prebiotics, or no additive

*

Table 1
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Means within the same row differ, P < 0.05.

1=Heinrichs et al., 1991 2=Heinrichs et al., 1990 3= Görgülü et al., 2003 4= Hill et al., 2009 5=Lesmiester et al.,
2004.
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*

Table 1 (continued)
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Mannanoligosaccharide Supplementation
Research in Ruminants
Mannanoligosaccharide (MOS) is a carbohydrate fraction of the yeast cell wall
that is not digestible, therefore as the bacteria attaches to MOS, it leaves the gut still
attached. Mannanoligosaccharide attracts certain gut bacteria such as E. coli, which has
an affinity for mannose fractions (Hill et al., 2009). In the past, oligosaccharides have
been used most frequently in the poultry and swine industries. The popularity of MOS is
becoming more familiar to the dairy industry as producers are encouraged to use other
products to increase gut health without the use of sub-therapeutic antibiotics. In a study
by Heinrichs et al. (2003), 72 Holstein calves were used to test the effects of MOS or
antibiotics in milk replacer. After being fed colostrum for 2 d, calves were then switched
to milk replacer (12.5% DM) containing 20% CP and 20% fat. Calves were assigned to
one of three treatment groups: Control (no additive), Antibiotic (400 g/440 kg of
neomycin + 200 g/440 kg of oxytetracycline) or MOS (4 g Bio-Mos per animal daily)
after being removed from dam. Milk replacer was fed twice daily until 6 wks of age.
Calves had ad libitum access to starter and water throughout the trial. Weekly samples
included body measurements and blood sample, while fecal and respiratory scores were
recorded daily. Heinrichs et al. (2003), reported, overall, calves fed antibiotics or MOS
had a higher probability (P < 0.01) for normal feces for the duration of the 6 week trial.
Regards to feed intake, there were no differences between treatment groups at the
beginning of the trial, however, at week 6, calves fed MOS consumed more starter than
calves supplemented with antibiotics (P < 0.05). No differences in growth or blood
parameters were found in this study. This study suggests the addition of MOS in milk
12

replacer may benefit overall calf health. According to manufacturer’s suggestion, the
recommended feeding amount of MOS varies from 4 to 10 g/d.
Table 2

Means of intake and performance of dairy calves fed antibiotic, MOS, or no
additives in milk replacer1

Body Weight, kg
Initial
Final
ADG, kg/d
Grain Intake, kg/d
Wk 1 to 5
Wk 6
a,b
Means differ; P < 0.05.
1
Heinrichs et al. (2003).

Control

Antibiotic

MOS

SE

51.4
66.5
0.36

51.5
67.2
0.38

51.4
65.7
0.34

1.1
1.3
0.03

0.130
0.850ab

0.117
0.793b

0.137
0.944a

0.012
0.047

Hill et al. (2009) compared the supplementation of MOS (3 g/d) or live yeast
(YST- 4 g/d) in a whole milk diet. All calves were fed 3.8 L colostrum once daily for 2 d,
then fed whole milk according to body size; Holsteins were fed 3.8 L/d and Jerseys fed
2.8 L/d. Calves were weaned at 42 d and remained on trial until 63 d of age. Body
measurements were taken weekly, while rectal temperatures, respiratory and fecal scores
were recorded daily. Feed and orts samples were pooled by month and analyzed for DM,
CP, NDF, and ADF according to AOAC protocols. No differences were observed by Hill
et al. (2009) in Holstein body weights (BW) among treatments, however, Jersey calves
supplemented with either MOS or YST had a greater BW at the end of the trial compared
to those with no supplementation. On average, fecal scores were lower (indicating less
scours) for Holstein calves fed MOS (1.35) or YST (1.26) compared to those with no
supplementation (1.46), which is consistent with Heinrichs et al. (2003) who reported
improved fecal scores in calves supplemented with MOS at a rate of 4 g/d. Because of its
13

immune boosting characteristic, MOS aids in the performance of animals when under
stress (Spring et al.,1998). Franklin et al. (2005) conducted a study to determine if
feeding MOS to close-up dry period dairy cows had an influence on cow immune status
or on the transfer of passive immunity to their calves. At 4 weeks pre-partum, immune
system parameters were monitored, blood samples were collected, and cows were
vaccinated against rotavirus, coronavirus, and E. coli toxoid. Fifty cows (30 Holstein, 20
Jersey) were randomly assigned to treatment approximately 3 weeks pre-partum to one of
two treatments: Control (18% CP, 3.1% fat) or control diet with MOS (10 g/hd/d). At this
time, cows were also weighed and moved to the close-up maternity pens. Two weeks prepartum, cows were vaccinated again and then one week before and at parturition, blood
samples were collected. Blood samples were analyzed for serum protein concentrations
(SPC), serum Ig concentrations, and rotavirus neutralization titers. Cows were given an
intramuscular injection of oxytocin and milked soon after calving to ensure the complete
removal of colostrum. Weight, temperature and quality of colostrum was recorded;
samples were frozen for later IgG analysis. At the second milking, cows were weighed.
Serum rotavirus titers were greater (P < 0.01) for Holsteins cows compared to Jersey
cows. Serum rotavirus titers were also greater (P = 0.04) for MOS-fed cows compared to
cows fed the control diet, indicating the potential for MOS-fed cows to have greater
passive transfer of immunity against rotavirus to calves. Calves were removed from dams
before suckling, they were weighed, bled via jugular venipuncture and fed maternal
colostrum (1.9 L Holstein and 1.2 L Jersey). The second feeding was 12 h after the first
and an additional blood sample was collected 24 h after the first bleeding. The quantity of
colostrum produced was greater (P = 0.04) for Holsteins compared to Jerseys, as was
expected, however, lactation number or MOS supplementation had no affect on the
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amount of colostrum produced. For calves born from MOS-fed cows, there was a
tendency (P = 0.08) for a greater increase in SPC from birth to 24 h of age. Franklin et al.
(2005) concluded that MOS supplementation to close-up dry cows may enhance transfer
of immunity to offspring, which may decrease the need for therapeutic antibiotics in
calves, leading to a decrease in morbidity and medical cost.
Research in Poultry and Swine
Saccharomyes cerevisiae (yeast) is the most common source for MOS however,
dried brewers yeast needs to be researched further as a source of MOS, which lead to the
following study. White et al. (2002) conducted 2 experiments, using brewers dried yeast
as a source of mannan oligosaccharides. The yeast contained 5.2% MOS. Agglutination
test were performed to confirm that brewers dried yeast would agglutinate gram-negative
bacteria having Type-1 fimbriae. The first experiment (28 d), 140 crossbred barrows and
gilts were used from the University of Kentucky Swine Research herd. These weanling
pigs were assigned to one of four treatment groups: Treatment 1- nonmedicated basal
diet, Treatment 2- basal diet plus 55 mg carbadox/kg, Treatment 3- basal diet with 3%
brewers dried yeast and Treatment 4- basal diet with 3% yeast and 2% citric acid. At the
end of weeks 2 and 4, fecal swabs were collected to evaluate microbial enumerations. At
the end of the experiment, one pig per pen was harvested for collection of intestinal
samples. In Experiment 2, a total of 24 cross bred pigs were used in a 39 day isolation
trial and assigned to one of three treatment groups. Treatment 1- basal diet, Treatment 2basal diet with 55 mg carbadox (antimicrobial agent)/kg or Treatment 3-basal diet with
3% yeast. Pigs were inoculated with E. coli K88 after a 29-d preliminary period. Fecal
samples were collected daily and intestinal samples were collected and analyzed
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postmortem from one pig per pen as in Experiment 1. Results from Experiment 1 over the
28 d test period showed reduced feed intake (633g and 636g, yeast and yeast + acid,
respectfully; P < 0.05) in pigs fed diets containing yeast leading to reduced growth rates
and weight gains (393g and 391g, yeast and yeast + acid, respectfully; P < 0.05). The
addition of yeast did not enhance growth performance. While the addition of yeast to pig
diets tended to decrease the total amount of coliforms (E. coli K88 and Carbadoxresistant coliforms) present at 14 and 28 d, it was not significant
≥ (P
0.10). Pigs in
Experiment 2 fed brewers yeast shed fewer (P < 0.05) total coliforms than pigs fed basal
diet. The addition of yeast and carbadox to pig diets resulted in reduced colonization of
total coliforms in the jejunum (P < 0.01) and cecum (P < 0.05). Figure 1 shows total
coliform counts in the jejunum were significantly different (P < 0.01) between pigs fed
the basal diet (2.86 ± 0.06) and those supplemented with carbadox (2.00 ± 0.06) or yeast
(2.22 ± 0.06).

Figure 1

Total Intestinal Coliform Counts 10 d after E.coli inoculation in weanling
pigs supplemented with brewers dried yeast- Exp. 2
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There was significant differences between pigs fed the basal diet (5.70 ± 0.12) and those
that received either carbadox (4.55 ±0.12) or yeast (5.16 ± 0.12) with respect to total
cecal coliform counts. It should be noted that greater differences in were observed
between basal and carbadox groups (P < 0.01) compared to basal and yeast groups (P <
0.05). According to the two experiments by White et al. (2002), the addition of 3%
brewers yeast to pig diets may not improve growth response as found in other studies.
Results from this study suggest that MOS may have a positive effect on immunoglobulins
leading to enhanced immune function as pigs fed brewers yeast tended to have higher (P
< 0.10) IgG and IgA levels. Davis et al. (2004) conducted a study to evaluate the effects
of phosphorylated mannans on growth and immune response of 32 weanling pigs. Pigs
were weaned on average at 19 d of age with an initial body weight of 5.7 ± 0.2 kg and
assigned randomly within 16 pens, with two pigs per pen. Pigs were fed one of two diets
both of which contained growth-promoting antibiotics (0.15 g of neomycin as neomycin
sulfate and 0.11 g of oxytetracyline per kg/feed) with one of the diets containing
phosphorylated mannans (0.3% of diet) substituted at the expense of corn in the basal
diet. Pigs were bled via vena cava puncture at the beginning of the trial, 14 d after
weaning and again just before euthanasia on d 19, 21, 24, and 26, respectively, via vena
cava puncture. Differential blood samples showed an increased lymphocyte percentage,
while the neutrophil percentage tended to decrease from pigs fed mannan diet.
Neutrophils are often associated as the first line of defense in sub-clinical and clinical
infection.

Alleviation of inflammatory responses due to stress of weaning and

improvements in gain and efficiency may all be supported by the trend of decreased (P <
0.08) neutrophil percentages in mannan-fed pigs, thus, phosphorylated mannans may
improve growth and immune response in weanling pigs. Pigs were slaughtered in order
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to collect 2 jejunal samples, which were used to isolate intraepithelial lymphocytes. On d
14 and 21 after weaning, BW and feed intake were measured to calculate ADG, ADFI
and gain:feed (G:F) ratio. Results from this study indicated greater (P < 0.05) ADG and
G:F, 0 to 14 d post weaning in pigs fed diets supplemented with mannans compared to
pigs fed basal diets. Overall (0 to 21 d, postweaning) pigs supplemented with
phosphorylated mannans performed better than pigs fed the basal diet with respect to
ADG (P = 0.03) and G:F ratio (P = 0.02). Implications from the current study suggest the
addition of phosphorylated mannans to newly weaned pigs may serve as a growthenhancer.
β-Glucan Supplementation
The pre-weaned calf’s digestive system functions similarly as those of some
monogastrics, specifically pigs. Therefore, research and the data collected using pigs as
the experimental unit can be very helpful in understanding the pre-ruminant calves and
their digestive systems. The study mentioned above by Hahn et al. (2006), is an example
of some data that may be reviewed and modified to fit a study using pre-ruminant calves.
β-Glucans are currently being studied by both human and animal scientist with
hopes to finding new products that improve gut health and overall gut function. Improved
weight gain, growth efficiency, disease resistance, and reduction in stress due to
environment and/or immune function, are all examples of the improvements that may be
made by supplementing β-glucans. β-glucans are immunomodulators derived from yeast
cell walls, much like MOS, and are linked polysaccharides. β-glucans may be found in a
variety of yeast and grains: yeast culture, yeast cell wall products, barley, oats, distillers
grains (wet or dry), and brewers grains. It is recommended that β-glucans be fed in
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concert with ascorbic acid (Vitamin C) to obtain the most effective results. The preferred
dosage of β-glucan supplementation is between 0.2 to 0.8 mg/ kg of BW, while the
preferred amount of Vitamin C is between 250 to 500 mg/kg of feed per day. In a study
conducted at the University of Missouri Swine unit by Eicher et al. (2006), 32 crossbred
pigs were used to evaluate the effects of Vitamin C and β-glucan as growth enhancers in
newborn pigs and as immunomodulators after an immune challenge in young pigs. Pigs
were assigned to one of four treatments: control, Saccharmyces cerevisae with β-glucan
(0.312 g/kg of BW, 2.5% of diet; Energy Plus, Natural Chem Industries, LTD, Houston,
TX), vitamin C (75 ppm), or β-glucan plus vitamin C (0.312 g/kg and 75 ppm,
respectively). Supplements were given via 10 mL of whole bovine milk within 36 h of
birth (after adequate colostrum intake and absorption) then daily until weaned at 2 wk of
age. Sows nursed pigs until weaning; then pigs were placed in individual pens and fed a
starter containing no additive (control), Saccharmyces cerevisae with β-glucan, vitamin
C, or β-glucan plus vitamin C. Body weights were recorded every third day until weaning
and then weekly after weaning. Treatment dosages were adjusted as pigs’ BW increased.
Pigs were challenged with 150 μg of lipopolysaccharide/kg of BW (LPS; Escherichia
coli serotype O111:B4) 14 d after weaning. Blood samples were collected every 0.5 h for
4 h via jugular catheter. ADG was greater (P < 0.05) in pigs supplemented with the
combination (β-glucan + Vitamin C) than those that received control or Vitamin C,
however, pigs supplemented with Vitamin C alone had lower (P < 0.01)) cortisol
concentrations than control. The interaction between Vitamin C and β-glucan showed a
trend (P = 0.07) for lower cortisol concentrations. It may be concluded from this study
that β-glucan and Vitamin C do in fact have immunomodulating effects in young pigs.
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Hahn et al. (2006) performed two experiments to evaluate the effects of β-glucans
on growth performance, nutrient digestibility and immunity in weanling pigs. In
Experiment 1, 210 weaned, males pigs were assigned to one of five treatments. βglucans were fed in the basal diet at levels of: 0, 0.01, 0.02, 0.03, or 0.04% of diet,
respectively. The purpose of Exp. 1 was to evaluate pig performance and conduct a
digestibility trial. This experiment was broken into two phases; Phase I (2 wk after
weaning) and Phase II (3 to 5 wk). During each phase, BW and ADFI were recorded. On
d 28, pigs were fed assigned treatment diets mixed with 0.25% chromic oxide as an
indicator and fecal samples were collected from all pigs between d 32 and 35. In
Experiment 2, 144 weanling, male pigs were assigned to one of four treatments: T1 (no
β-glucan or anitibiotics), T2 (0.02% β-glucan), T3 (antibiotic) or T4 (0.02% β-glucan and
antibiotics). The antibiotics fed during this experiment were separated into two phases.
Phase I, was between wk 0 to 2, was 0.15% apramycin and 0.10% carbadox. Phase II (wk
3 to 8) antibiotics were: 0.10% chlortetracycline and 0.10% carbadox. Pig performance
and digestibility was evaluated the same as Exp. 1 and the immune response was studied
until wk 8 (end of trial). The digestibility results showed a linear increase as dietary βglucan was increased in DM, GE, CP, EE, and P. Overall ADG was greater (P < 0.05) for
pigs fed T4 diet compared to T2 or T1, but was similar to pigs fed T3 diet. Final
observations from this study suggest that antibiotics may be more effective in regards to
nutrient digestibility and growth performance in young pigs compared to β-glucan.
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Table 3

Overall growth performance of weanling pigs fed different concentrations of
β-glucan1,2
β-glucan, %

Parameter
ADG, g/d
Feed Intake, g/d

0

0.01

0.02

0.03

0.04

SEM3

363
589

380
608

401
642

403
629

402
621

28.0
37.9

1

Each mean represents 3 pens with 14 pigs each.
Hahn et al. (2006).
3
Pooled SEM.
2

Table 4

Overall growth performance of weanling pigs fed antibiotics, β-glucan, or
no antibiotics1

Treatment2
Parameter
T1
T2
T3
T4
SEM3
ADG, g/d
355
376
386
403
23.6
Feed Intake, g/d
495
504
488
536
31.6
a,b
Means within a row without a common superscript differ, P < 0.10.
c-e
Means within a row without a common superscript differ, P < 0.05.
1
Hahn et al. (2006).
2
Four treatment diets: T1 (no β-glucan or antibiotics; control), T2 (0.02% β-glucan),
T3 (antibiotic) and T4 (0.02% β-glucan + antibiotic).
3
Pooled SEM.

The current study is an example of a trial that may be reviewed and modified to fit a
study using pre-ruminant calves. In agreement with the Hahn et al. (2006) study, Dritz et
al. (1995) found no positive influence on pig growth performance, immune response, or
neutrophil and macrophage function, by adding 0.1% β-glucan to diets. However, pigs
supplemented with 0.025% β-glucan had increased (P < 0.02) ADG, 28 d post-weaning.
This evidence supports the idea of supplementing pigs with 0.025% β-glucan would
increase growth performance.
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Growth and Development
As a calf ages, it undergoes many physiological changes involving overall body
development, rumen development, and the ability to cope with immune challenges. From
birth until weaning, calf development is broken down into 3 phases: liquid-feeding phase
(pre-ruminant), transition phase, and ruminant phase (NRC, 2001). During the liquidfeeding phase, calves rely solely on milk or milk replacers to meet nutrient requirements.
The esophageal groove plays an important role during this phase, as it redirects milk or
milk replacer into the abomasum, avoiding microbial breakdown in the reticulo-rumen
(Orskov, 1972). Stimulation of the esophageal groove to close may be induced by visual
and other stimuli such as: presence of caretaker or noises associated with feeding (Moran,
2002). As the calf ages, it begins to rely on both liquids and solids (starter grain) for
nutrients, this is considered the transition phase. By the time the calf reaches the ruminant
phase, it is completely reliant on solid feeds to meet nutrient requirements (NRC, 2001).
For calves 2-3 weeks of age, receiving proper nutrition as their bodies transition into fully
functional ruminants is crucial.
Pre-Ruminant Phase
Shortly after birth, a calf needs to receive adequate quality and quantity
colostrum, which is the cornerstone to health and longevity. Colostrum contains
numerous antibodies, including immunoglobulins, which help boost the immune system
of the neonatal calf, which are absorbed by the small intestine. Calves are born with no
immunity, therefore, it is vitally important to ensure the calf receives high quality
colostrum. It is recommended that a newborn calf receive between 3 and 3.8 L of
colostrum, depending on breed, containing at least 100 g of Immunoglobulin G (IgG)
from multiparous cows within the first hours of birth (NRC, 2001). As time passes and
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the calf gets older, the amount of immunoglobulins able to be absorbed decreases. Once
the calf is 24 hours of age, no immunoglobulins may be absorbed. Hammon and Blum
(1998) point out the necessity of colostrum due to the number of hormones and growth
factors it contains, which are key for growth and development of the digestive tract and
other organ systems.
As of 1995, 60% of U.S. dairy farms used milk replacers for some or all of the
neonatal calf feeding (Heinrichs et al., 1995). In regards to quality, milk replacers are a
very good source of liquid feed for neonatal calves (Heinrichs et al., 1995). Heinrichs et
al. (1995) concluded from a study that focused on types of milk replacers used across
dairies in the U.S. that producers in the southeast tended to feed less whole milk than
those in other parts of the country. There are many influences that may sway producers
either to use milk replacers or not, including: economics (price of milk/cwt), size of herd,
and availability of waste milk. The quantity of milk replacer to be fed per calf is based on
an equation for metabolizable energy (ME) by Toullec (1989):
ME requirements (Mcal/d) = 0.1 LW0.75 + (0.84 LW0.355) (LWG1.2)

(2-1)

where: LW (live weight) and LWG (live weight gain) are in kilograms. This formula is
set in two different portions. The first sets the ME requirements at 100 kcal/kg0.75 per day,
while the second portion is used to derive ME required for LWG. Quality of milk
replacer is important not only for overall health status, but also for the progression of
rumen development. A calf’s rumen is not fully functional until after weaning, therefore,
it is crucial that milk replacers contain proteins able to be used by the calf. As mentioned
previously, the esophageal groove redirects milk from the reticulo-rumen and into the
abomasum. Milk or milk replacer clots when it reaches the abomasum and is then broken
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down by enzymes rennin and pepsin. The clotting causes the rate of passage to slow,
allowing the nutrients to be released at a steady pace (Moran, 2002). Protein sources and
content may vary among milk replacer manufacturers. Examples of possible protein
sources include: milk solids, skim milk, casein, whey protein concentrate, soy flour and
animal (porcine and bovine) plasma protein (Davis and Drackley, 1998). According to
Davis and Drackley (1998) there are two classifications of protein sources from which
milk replacers are made of; milk or non milk proteins. Generally, milk protein sources
(dried whey, skim milk and casein) are more desirable because they are highly digestible,
have more desirable amino acid balance and tend to have less anti-nutritional factors than
non milk sources. Major milk replacer manufacturers use whey proteins as the principle
protein source as they allow for the manufacturers to produce a high quality product.
Protein content will typically range from 18 to 24% crude protein, which is crucial to
support adequate calf growth. Bartlett et al. (2006) discovered calves reached optimum
efficiency when fed 22% CP compared to 14, 18 or 26% CP. Fat levels also vary in milk
replacers from 10 to 24 percent with 15 to 20 percent being the most common. Because
fats serve as an energy source of calves, quite often, a milk replacer with a higher fat
level will be used in cold climates.
Transition Phase
Between weeks 2 and 3, the calf’s digestive tract begins to undergo the most rapid
changes with regard to digestible secretions and enzymatic activity (Toullec and
Guilloteau, 1989; Davis and Drackley, 1998). Starter grain is generally offered to calves
within the first two weeks of life and then continued through weaning. Ad libitum water is
also provided to encourage starter consumption (NRC, 2001). Starter grains should be
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highly palatable and meet the energy needs of each calf according to NRC Guidelines.
Sander et al. (1959) concluded that the consumption of starter grain is critical in the
development of an active, functioning rumen and also; solid feeds are responsible for the
development of functional ruminal epithelial tissue. Reports show VFA concentrations
are similar in calves consuming starter diets, as early as 3 weeks of age compared to
those in adult cattle. Roth et al. (2009) conducted a weaning method trial using 26 Brown
Swiss, 14 red Holstein, and seven Holstein-fresian calves. The objective of this trial was
to analyze feeding behavior recorded via a feed intake-montoring computer as an
appropriate method for predicting health status and rumen development. The calves were
assigned to one of two treatment groups (conventional weaning or concentrate-dependant
weaning). Both groups of calves were fed 6L of milk daily with ad libitum access to
water. The conventionally weaned calves’ milk was continuously reduced from weeks 8
to 12. Once they reached 12 weeks of age, calves were completely weaned from milk.
These calves were only allowed grain according to their calculated nutritional
requirements. For the concentrate-dependent weaned calves, the amount of concentrate
was dependent upon each calf’s individual feeding plan. Once calves consumed 700g of
concentrate over 4 consecutive days, milk allowance was reduced. When calves
consumed 2000g or more, 4 consecutive days, milk feeding was abruptly stopped.
Calves in the concentrate-dependent weaning group were weaned at an average age of 76
d, while the conventionally weaned group had an average weaning age of 84 d. On
average, concentrate-dependent weaned calves gained 0.88 kg/d, while conventionally
weaned calves gain 0.87 kg/d. Roth et al. (2009) concluded faster physiological
development without negative effects on rumen development, weight gain, or health
status may be achieved by using the concentrate-dependent weaning method. Results
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from this study showed that weight gain was a rather accurate measurement to determine
rumen development. However, evaluation of rumen pH and VFA production are more
common practices in determining rumen development. Calves fed grain diets with little to
no roughage have in fact been shown to have increased VFA concentrations (Klein et al.,
1987). Butyrate, in particular, is said to increase metabolic activity of the ruminal
epithelium (Sutton et al., 1963).
Ruminant Phase
Once a calf is weaned (4 – 6 weeks of age) completely from its liquid diet, the
rumen is beginning to be function. The rumen is not fully functional until the calf is
approximately four months of age. As the calf ages and the rumen continues to develop
and microbial populations increase. The rumen microbes must possess certain
characteristics (anaerobic and fast growth in pH ranges from 5.0 to 7.0) in order to aid in
a fully functional rumen. The esophageal groove no longer plays a role in the redirection
of a liquid diet, allowing for solids to enter into the rumen to be broken down. Microbial
fermentation now occurs in the reticulo-rumen (NRC, 2001). During this phase, the calf
is relying on grain, forage, and other dry feeds to obtain nutrient requirements. Calves are
sometimes offered a forage source (hay) with the intent rush rumen development, when
in fact, the development of a fully functional rumen is not necessarily promoted by a
forage source, but with a highly fermentable feed source. A good indicator of a wellfunctioning rumen, is the presence of VFA’s (Volitile Fatty Acids: butyrate, proprionate,
and acetate), which is yielded by forage sources in much lower concentrations than grain
sources. With this said, it is not recommended to completely eliminate forage or fiber
sources from the starter diet. It is important to provide the calf with a well-balanced diet
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along with access to plenty of water to encourage dry matter intake to aid in the
continuing of rumen development as well as overall body growth.
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CHAPTER III
MATERIALS AND METHODS
Animals and Housing
Forty Holstein heifer calves (n=8) were used in the current trial at the Bearden
Dairy Research Center at Mississippi State University. At birth, calves were randomly
assigned to one of five different treatment groups. Treatments were as follows: CX (1 g/d
Deccox), YST (10 g/d yeast), β-g (0.5 g/d β-glucan), CX + YST (1 g/d Deccox + 10 g/d
yeast) and YST + β-g (10 g/d yeast + 0.5 g/d β-glucan). Treatments were noted as 1,2,3,4
and 5, respectively. The YST additive contained 50% mannanoligosaccharide and 25% βglucan fractions. Treatment additives were mixed with 100 mL warm water and then
added to milk replacer at feeding. Calves were individually housed in plastic hutches
made by Calf Tel® which were bedded with wheat straw. In order to maintain a dry,
insulated environment for calves, additional wheat straw was added as needed. Nose-tonose contact between calves was eliminated by hutch arrangement. The trial was
conducted over an eight week period, where calves were weaned at six weeks of age and
remained in hutches until eight weeks of age. Calves were fed 3.8 L (710 g powder) of a
non-medicated milk replacer (22% CP, 20% Fat; DM)from an open pail once daily at
0630 until d 35, at which daily milk allowance was then reduced to 1.4 L (355 g powder).
At d 42, calves were weaned. After milk feeding, buckets were rinsed and filled
with water, allowing calves ad libitum access to water until next feeding. A nonmedicated starter grain (18% CP) was offered in increments of 0.9 kg/d starting at 1 day
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of age. When a calf had no feed refusals, grain allowance was increased by 0.9 kg/d. All
40 calves used for this study were born between September 2009 and February 2010.
Data Collection
Growth Performance
Calves were separated from dams by 12 h after birth. At that time, calves received
2.83 L of colostrum via esophageal feeding tube. A single blood sample was collected via
jugular venipuncture between 2 and 7 d after birth to ensure adequate time for IgG
absorption. Immunoglobulin G (IgG) concentrations were determined using a single
radial immunodiffusion kit (VMRD Inc., Pullman, WA). Body weight (BW), hip height
(HH), hip width (HW), wither height (WH) and body length (BL) was measured at birth,
once weekly and the final day of trial. Rectal body temperatures were also recorded
weekly. Orts were collected and weighed daily and then pooled by treatment for weekly
feed analysis. Analyses of feed samples were completed in the Scales Nutrition
Laboratory in the Animal and Dairy Sciences Department at Mississippi State University
for dry matter, nitrogen, Fat, Neutral Detergent Fiber and Acid Detergent Fiber
(according to AOAC methods).
Health status and blood sampling
Respiratory and fecal scores were evaluated and recorded daily at feeding
according to Larson et al. (1977). Briefly, fecal scores were determined based on a 5
point scale where 1 represented normal (soft, solid, no fluid), 2 soft (semi-solid), 3 Runny
(soft, mostly fluid), 4 Watery (fluid) and 5 bloody. Respiratory scores were as follows: 1normal, 2- runny nose, 3-heavy breathing, 4-moist cough and 5-dry cough. Two blood
samples were collected once weekly (Wednesdays), 4 hours after feeding; one 5 mL
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vaccutainer containing EDTA for complete blood count (CBC) analysis with differential
and one 10mL vaccutainer containing no anticoagulant. Samples were immediately
transported (11 km) to the laboratory. The whole blood samples were analyzed for CBC
in the Animal Pathophysiology Laboratory of the College of Veterinary Medicine at
Mississippi State University. The blood samples containing no anticoagulant were
processed in the Animal Physiology Lab at Mississippi State University; centrifuged at
3000 x g at 4 degrees C for 30 minutes and then serum was stored in 1.5 mL
polypropylene tubes at -20 degrees C until further analysis of cortisol concentrations.
Cortisol samples were analyzed via radioimmunoassay (Coat-A-Count, Siemens
Healthcare Diagnostics Inc., Los Angeles, CA).
Fecal Sampling
Fecal samples were collected weekly until calves reached 21 d of age and then
twice weekly to analyze for the presence of coccidia. Analyses were conducted in the
Animal Pathophysiology Laboratory of the College of Veterinary Medicine at Mississippi
State University. Samples were graded subjectively based on the number of oocyst
present: None (0), Rare (1 to 5), Few (10 to 25), Moderate or Many ( >25). Twice weekly
fecal samples were collected once calves reached 21 d of age due to the 21 d lifecycle of
coccidia. Fecal E. coli shedding was recorded and analyzed by taking a fecal sample from
each calf at weeks 2, 4 and 8. A sterile 10 μL loop of fecal material was placed into 990
μL of Luria-Bertani (LB) broth. A serial dilution was conducted to yield a 10-4 dilution
and was then plated on MacConkey agar. Plates were incubated for 24 hrs at 37˚C. After
incubation time was complete, colony forming units (CFU’s) were counted.
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Feed Analysis
Grain refusals (orts) were collected and measured daily and then pooled by
treatment for weekly feed analysis. Analyses of feed samples were completed in the H.W.
Essig Nutrition Laboratory in the Animal and Dairy Sciences Department at Mississippi
State University (according to AOAC methods). All samples were first dried for 48 hrs in
a 64˚C drying oven to obtain an “Air Dry” basis. Samples were then ground in a Willy
Mill through a 2- mm screen. Samples were analyzed in duplicate: DM, N, Fat, NDF and
ADF.
Statistical Design and Analysis
A completely randomized design was used as the experimental design of this
project. Class variables included Calf_ID, treatment, and week. All data were analyzed
using the MIXED procedure of SAS (version 9.2). Orthogonal contrast statements were
used to determine differences between treatments if present, the contrast statements were:
YST vs. β-glucan, YST vs. YST + β-glucan, β-glucan vs. YST + β-glucan and CX vs. all.
Data sets containing multiple measures per calf were analyzed by ANOVA for repeated
measures. Treatment differences with P≤ 0.05 were considered significant, while P ≤
0.10 were considered a tendency.
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CHAPTER IV
RESULTS AND DISCUSSION
Calf IgG concentrations were adequate for passive transfer of immunity in all
calves in the present study. Nutrient intake was not different and as expected, growth
measures among treatment groups were similar (P≥ 0.05; Table 1). Calves were fed the
same basal diet, therefore, no differences were expected among treatments due to diet.
Similar to findings of Lesmiester et al., (2004) and Morrill et al., (1995), and Galvão, et
al. (2005) no differences were observed between treatment groups with respect to blood
parameters (P ≥ 0.05; Table 2). The effects of 1 or 2% live yeast culture (Lesmiester, et
al., 2004 and Galvão, et al. (2005) or probiotics (Morrill et al., 1993) did not change total
plasma protein concentrations when compared to control fed calves. Weekly body
measurements were recorded and analyzed and no differences were found among
treatments for BW, WH, HH, HW or BL (P = 0.52, 0.21, 0.19, 0.53 and 0.39,
respectively). Hill et al. (2009), Hill et al. (2008), and Heinrichs et al. (2003) all
supplemented Holstein calves with MOS and compared to calves with no
supplementation of antibiotics, yeast, or coccidiostat, there were no differences in
growth. Heinrichs et al. (2003) did however, report differences in grain intake during
week 6 compared to calves fed antibiotics, while Hill et al. (2009) saw no change in
starter intake due to supplementation of MOS in Holstein calves. Improved grain intakes
(P < 0.05) were observed in calves supplemented yeast culture in starter grain compared
to control, while a tendency (P < 0.10) for greater starter grain intake was shown by
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calves supplemented with yeast culture in milk replacer compared to control (Galvão, et
al., 2005). It can be noted that grain intake for calves fed yeast culture in both milk
replacer and starter grain did not differ from other treatment groups. Lesmiester et al.
(2004) found similar results when calves were supplemented 1 or 2% yeast culture in
starter grain. Overall (wk 1 to 6) intakes were significantly higher (P < 0.01) for calves
fed 2% yeast culture. No differences were found in fecal and respiratory scores or rectal
temperatures (P ≥ 0.05) among any treatment groups. These observations were similar to
Galvão, et al. (2005), who found the addition of live yeast products in calf diets had no
effect (P > 0.10) before or after weaning. In contrast, Heinrichs et al. (2003), Hill et al.
(2009) and Magalhães et al. (2008), found calves fed MOS or yeast had a higher
probability for more normal feces, lower average fecal scores, and/or fewer days
scouring. Similar fecal coccidia scores (P = 0.77) were observed between treatment
groups from weeks 0 to 8. Our findings are different from Heinrichs et al. (1991),
Heinrichs et al. (1990) and Waggoner et al. (1994) who all found differences in coccidia
shedding in calves treated with a anticoccidial, with shedding rates being greater for
calves treated compared to control. Among all 40 calves in this study, cortisol
concentrations ranged from 0.22 to 126.19 ng/mL over the course of the trial, while there
were no differences between treatments (P = 0.92) the effect of week, was significantly
different (P < 0.01) over the eight week course of the trial. These findings are similar to
those of Cummings and Brunner (1990) who conducted a housing trial with colostrumdeprived Holstein calves. No differences (P≥ 0.05) were observed in blood nitrate or
nitrite concentrations among treatment groups. Heifers fed YST or YST + β-glucan had
higher (P = 0.02 and P < 0.01, respectively) fecal concentrations of E. coli compared to
heifers fed CX, CX + YST, or β-glucan alone. Fecal E. coli concentrations were lower (P
33

< 0.05) in week 8 when compared to weeks 2 and 4. This decrease in concentrations may
be a result of weaning, when additives were no longer included in the diet.
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CHAPTER V
CONCLUSIONS AND IMPLICATIONS
The objectives of this study were to evaluate the efficacy of using antibiotic
alternatives such as MOS and β-glucan on calf growth and health performance and feed
intake/efficiency. The purpose of this study was also to evaluate the effects these
products have on E. coli and coccidia shedding. Based on the results found, feeding these
products at the given dosages, had no beneficial impact on growth and health
performance, which includes feed intake and efficiency, fecal and respiratory health and
blood parameters, however, these products had no negative effects on calf performance
and are comparable to performance of calves supplemented with coccidiostats. All calves
were healthy throughout the duration of the trial and no clinical signs of coccidiosis or
respiratory infections were observed. Feeding these products may serve as a viable source
of gut health enhancers, therefore reducing the need for non-therapeutic antibiotic use
and the cost associated with them. The E. coli shedding results in the current study may
be an indication of the gram (-) binding and non-digestible properties of YST, which
increased E. coli

shedding, serving as a suitable product to aid in balancing gut

microflora, which ultimately leads to a healthy, productive calf. Further investigation is
needed to determine the optimum dose and feeding method (example: milk/milk replacer
or starter grain) of these products to maximize efficacy, while being an economical
solution for producers to increase calf productivity.
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Figure 2

Growth performance of Holstein heifers fed CX, YST, β-glucan, or some
combination
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Table 5

Nutrient Intake and Growth Measures in Holstein heifers fed CX, YST, βglucan, or some combination
Treatment

DMI: Starter grain, kg/d
Period 11
Period 22
Period 33
DMI: Milk, kg/d
Period 1
Period 2
Period 3
DMI: Total4, kg/d
Period 1
Period 2
Period 3
CP Intake: Total, kg/d
Period 1
Period 2
Period 3
NDF Intake: Starter, kg/d
Period 1
Period 2
Period 3
ADF Intake: Starter, kg/d
Period 1
Period 2
Period 3
Initial BW, kg
Final BW, kg
ADG, kg/d
Feed Efficiency5

P<

CX

YST

β-glucan

CX +
YST

YST + βglucan

SEM

Trt

Period

0.1
0.58
1.61

0.17
0.8
1.88

0.19
0.8
1.72

0.14
0.64
1.62

0.17
0.92
1.9

0.08
0.09
0.08

0.25

0.01
0.01
0.01

0.71
0.35
0

0.71
0.35
0

0.71
0.35
0

0.71
0.35
0

0.71
0.35
0

-

0.81
0.93
1.61

0.88
1.16
1.88

0.91
1.15
1.73

0.85
0.99
1.63

0.88
1.28
1.9

0.08
0.09
0.08

0.25

0.001
0.001
0.001

0.16
0.18
0.31

0.17
0.23
0.36

0.18
0.23
0.32

0.17
0.2
0.31

0.17
0.25
0.38

0.02
0.02
0.02

0.29

0.001
0.001
0.001

0.02
0.12
0.34

0.04
0.17
0.4

0.03
0.14
0.32

0.03
0.12
0.31

0.03
0.17
0.32

0.02
0.02
0.02

0.26

0.001
0.001
0.001

0.01
0.05
0.13

0.02
0.07
0.16

0.02
0.06
0.14

0.01
0.05
0.12

0.01
0.08
0.13

0.01
0.01
0.01

0.28

0.001
0.001
0.001

39.2
61.9
0.41
0.39

39.1
64.9
0.46
0.4

39.5
67.7
0.5
0.44

38.1
64.4
0.47
0.42

41.1
67.3
0.48
0.4

1.23
2.67
0.04
0.02

>0.05
>0.05
>0.05
>0.05

-

1

Period 1 = d 1 to 34, 2 Period 2 = d 35 to 41, 3Period 3= d 42 to 55,
4
Total DMI= Starter DMI + Milk DMI, 5 Feed Efficiency = Gain/Feed
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Table 6

Mean Blood Parameters in Holstein heifers fed either CX, YST, β-glucan,
or some combination from 0 to 8 weeks of age
CX

MOS

CX +
MOS

MOS + βGLUCAN

Blood Parameters
7.73
8.29
8.80
8.27
8.48
20.2
10.8
11.3
11.7
28.2
31.0
31.4

SEM

P-value

0.65
5.42
0.42
1.17

≥0.05
≥0.05
≥0.05
≥0.05

White Blood Cells, K/ul
Red Blood Cells, M/ul
Hemoglobin, g/dl
Hematocrit, %

8.39
8.40
10.7
29.1

Platelets, K/ul

1264 1118

1290.2

926

1229

125

≥0.05

Plasma Protein, g/dl

5.97 6.71
3455 3589

5.95
3332

6.09
3336

6.09
3643

0.37
401

≥0.05
≥0.05

4829 3973
346 305
52.3 43.0
43.7 30.0

4073
337
17.3
16.8

4425
270.6
37.5
44.3

4806
261.5
25.9
36.9

351
77
13.7
9.82

≥0.05
≥0.05
≥0.05
≥0.05

Neutrophil, #/ul
Lymphocyte, #/ul
Monocyte, #/ul
Eosinophil, #/ul
Basophil, #/ul

Table 7

7.92
8.44
11.0
30.2

βGLUCAN

Nitrate, Nitrite and Cortisol concentrations in Holstein heifers fed yeast
derivatives in milk replacer from 0 to 8 weeks of age

Item

CX

Nitrate, ppm
Nitrite, ppm
Cortisol, ng/mL

19.1 22.6
0.63 0.59
14.4 15.6

Table 8

YST

Treatment
βCX +
glucan YST
25.7
24.7
0.64
0.66
13.6
15.4

YST + βglucan
22.0
0.68
15.9

SEM P-value
7.77
0.09
1.98

≥0.05
≥0.05
≥0.05

Fecal Coccidia counts in Holstein heifers fed yeast derivatives in milk
replacer from 0 to 8 weeks of age

Item

CX

YST

None
Rare
Few
Moderate
Many

72
15
7
6
0

79
12
8
2
2

Treatment
β-glucan CX + YST
71
20
8
3
0

75
16
7
5
0

38

YST + βglucan
74
11
9
6
2

Chi-Sq <
0.65

Figure 3

Fecal E. coli concentrations of Holstein heifers fed CX, YST, β-glucan, or
some combination
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